Mix & match. Save up to 25%. Shop now

Sold OutStock InboundKLOW Blend 80mg

KLOW Blend 80mg

฿4,390

Bundle and save
Bundle & save up to 25%Mix & match. Every vial in your cart counts.

Awaiting stock

The lab report for the vial you’ll get.

Every batch is tested before it goes on sale. The report appears here when the next batch is released.

KLOW Blend 80mg

Awaiting lab release

The batch number, results and signed report appear here as soon as this size is released.

What’s in the vial.

KLOW is a co-lyophilized research blend of GHK-Cu, BPC-157, TB-500, and KPV, studied together in dermal and tissue-repair research.

For laboratory research use only
In this vial
80 mg total co-lyophilized powder
Blend of
GHK-Cu 50 mg + BPC-157 10 mg + thymosin beta-4 10 mg + KPV 10 mg
Store sealed
−20°C · protect from light
Once mixed
2-8°C · follow your lab protocol for how long

Four components. Clearly separated research context.

The selected studies address individual components and model-specific endpoints. They do not establish synergy, clinical efficacy or an equivalent response for this four-component formulation.

  • GHK-Cu

    A copper-coordinated tripeptide studied in fibroblast, extracellular-matrix and copper-signaling research.

  • BPC-157

    A synthetic 15-amino-acid peptide investigated mainly in preclinical migration, vascular-signaling and connective-tissue models.

  • Thymosin beta-4

    A 43-amino-acid actin-binding peptide studied in cytoskeletal organization, cell migration and tissue-repair models.

  • KPV

    A Lys-Pro-Val tripeptide derived from the C-terminal sequence of alpha-MSH and studied in cellular inflammatory-signaling and experimental intestinal models.

Common questions

Research context, batch testing, storage and verification for KLOW Blend 80mg.

What is KLOW Blend 80mg?

KLOW Blend 80mg is a co-lyophilized research formulation containing 50mg GHK-Cu and 10mg each of BPC-157, thymosin beta-4 and KPV. It is supplied strictly for in-vitro and laboratory research.

How much of each component is in the vial?

The labeled total is 80mg: GHK-Cu 50mg, BPC-157 10mg, thymosin beta-4 10mg and KPV 10mg. The current batch-specific net-content result will be published in the matching Certificate of Analysis.

Has KLOW Blend been studied as this exact formulation?

The selected literature concerns the individual components. It should not be interpreted as direct evidence of synergy, equivalence or a proven combined effect for the fixed four-component formulation.

What is KPV?

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone. Published research includes cellular inflammatory-signaling work and experimental intestinal models.

What research context applies to the other three components?

GHK-Cu, BPC-157 and thymosin beta-4 have separate preclinical research records involving extracellular-matrix endpoints, cell migration, actin binding and tissue-repair models. Findings for one component do not establish behavior of the blend.

Scroll to Top